Phi Pharma SA is developing a new class of anti-cancer drugs: Peptide Drug Conjugates (PDCs) effective in multiple human cancers using an innovative mechanism of cell entry: novel CSPG4 targeting bio-pharmaceuticals.

Location
Canton
Facts & figures
  • Type of organization
    Private company
  • Year of foundation
    2012
  • Number of employees in Switzerland
    1-9
Key business

You may also be interested in